• Forsythoside E: PKM2 Inhibitor for Immunometabolic Research

  2026-05-15

  Forsythoside E stands out as a mechanistically precise pyruvate kinase M2 (PKM2) inhibitor, enabling robust immunometabolic investigations in sepsis-induced liver injury and macrophage polarization. This guide translates bench protocols, troubleshooting, and comparative innovations into actionable steps for researchers seeking reliable results.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-14

  This study uncovers how IGF2BP3, acting as a dominant m6A reader, stabilizes FZD1/7 transcripts to promote cancer stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). The mechanistic findings establish a novel RNA regulatory axis as a therapeutic vulnerability, with implications for targeting cancer stem cells and improving chemotherapy outcomes.

• Omicron KP.3 RBD mRNA Vaccine: Broad Neutralization in Mice

  2026-05-14

  This study presents a newly designed mRNA vaccine encoding the Omicron KP.3 receptor-binding domain (RBD), demonstrating robust antibody responses and broad neutralization against multiple SARS-CoV-2 Omicron subvariants in mice. The work highlights both the technical advances in antigen design and the practical implications for next-generation mRNA vaccine development.

• Vitamin C in Organoid Cancer Research: Protocols and Innovat

  2026-05-13

  Vitamin C (ascorbic acid) is transforming preclinical cancer and virology research through its dual role as an apoptosis inducer and tumor proliferation inhibitor. This article guides advanced experimental design using high-purity Vitamin C in organoid and animal models, spotlighting protocol optimization, troubleshooting, and the pioneering use of multilineage organoids in antiviral discovery.

• Go 6983 Pan-PKC Inhibitor: Precision Tools for PKC Pathway R

  2026-05-13

  Go 6983 (pan-PKC inhibitor) empowers researchers to dissect PKC-driven processes with nanomolar precision, enabling sophisticated cancer, EMT, and neurobehavioral studies. This guide translates recent mechanistic advances and experimental best practices into actionable workflows, troubleshooting tips, and protocol enhancements.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-05-12

  This study establishes and characterizes patient-derived, three-dimensional spheroid cultures from organ-confined prostate cancer tissue. The model offers a translational platform for in vitro drug response analysis and addresses longstanding limitations of conventional cell lines.

• D-Luciferin: Optimizing Firefly Luciferase Substrate Workflo

  2026-05-12

  D-Luciferin empowers non-invasive, high-sensitivity quantification of ATP and tumor burden in vivo and in vitro. APExBIO's expertly validated substrate supports robust workflows for translational oncology and immuno-oncology, with actionable guidance for maximizing data quality and troubleshooting complex experimental scenarios.

• Busulfan (SKU A8386): Precision in Senescence & Germ Cell Re

  2026-05-11

  This article delivers scenario-driven guidance for deploying Busulfan (SKU A8386) as a robust DNA alkylating agent in cell viability and germ cell depletion assays. Drawing on validated protocols and recent genetic tracing studies, it addresses real lab challenges—optimizing reproducibility, interpreting cytotoxicity data, and selecting reliable suppliers. Readers gain actionable insight into Busulfan’s applications in senescence induction and germline modeling, grounded in quantitative evidence and best practices.

• Angiotensin I Decapeptide: Precision Tools for RAS Research

  2026-05-11

  APExBIO’s Angiotensin I (human, mouse, rat) empowers cardiovascular and neuroendocrine research with reproducible, high-fidelity performance. Discover advanced workflows, troubleshooting strategies, and cross-study insights for optimal renin-angiotensin system modeling.

• RITA (NSC 652287): Transforming Renal Carcinoma Workflows

  2026-05-10

  RITA (NSC 652287) delivers potent, selective p53 activation in renal carcinoma research, enabling precise apoptosis assays and robust tumor xenograft outcomes. This article details advanced protocol tweaks, troubleshooting strategies, and workflow innovations grounded in recent cancer biology methodology.

• Lipid Scrambling Modulates Ferroptosis and Tumor Immunity

  2026-05-09

  Yang et al. reveal that TMEM16F-mediated lipid scrambling on the plasma membrane acts as a late-phase suppressor of ferroptosis, protecting cells from membrane collapse and promoting tumor immune evasion. Their work identifies lipid scrambling as a promising therapeutic target, with implications for cancer immunotherapy and redox biology.

• Chloroquine in Translational Research: Mechanisms and Strate

  2026-05-08

  Explore the mechanistic depth and strategic edge of Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) for translational researchers. This thought-leadership article integrates molecular insights, competitive context, protocol guidance, and a forward-looking vision, positioning APExBIO’s Chloroquine as a cornerstone for rigorous and innovative studies in autophagy, immune signaling, and disease modeling.

• Fulvestrant (ICI 182,780): Advanced Workflows for ER Antagon

  2026-05-08

  Fulvestrant (ICI 182,780) enables precise targeting of estrogen receptor signaling in breast cancer models, combining robust ERα degradation with proven synergy in chemotherapy sensitization. Discover optimized protocols, troubleshooting insights, and practical translation of recent immunomodulatory research to supercharge your endocrine therapy resistance studies.

• Hydrocortisone in Translational Research: Mechanisms to Mode

  2026-05-07

  This article explores hydrocortisone’s mechanistic role in translational research, focusing on its impact in inflammation model systems, stress response mechanisms, and neuroprotection, while offering strategic guidance for protocol optimization. Drawing on the latest mechanistic research and leveraging STAMBPL1/TRIM21 axis insights, we contextualize APExBIO’s hydrocortisone as a benchmark tool for translational scientists navigating the evolving landscape of immune modulation and disease modeling.

• AMD-070 Hydrochloride: Empowering Precision CXCR4 Antagonist

  2026-05-07

  Mavorixafor hydrochloride (AMD-070 hydrochloride) from APExBIO stands out as a potent and selective CXCR4 antagonist, enabling advanced workflows in anti-HIV research, rare disease modeling, and cell migration studies. This guide distills evidence-based protocols, advanced troubleshooting, and novel insights from landmark studies—bridging foundational mechanisms to robust, reproducible experimental success.

11778 records 1/786 page Next 12345 下5页 Last page